Johnson & Johnson (NYSE:JNJ)’s Spravato is reinforcing investor interest in the broader psychedelics sector as it reported ...
Johnson & Johnson reported first-quarter sales above Wall Street’s expectations and bumped up its outlook for the year, led ...